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To the Editor—When making inferences regarding efﬁcacy and
answering the question “does (did) this treatment do something
to someone?” analysis of individual trials, with their high degree
of internal validity, is the gold standard. Nevertheless, when
attempting to predict the comparative effectiveness of the range
of potential treatments for a speciﬁc future patient, consideration
of the set of trial evidence is essential. This consideration is aided
by the statistical analysis of the set or network of trial evidence.
Network meta-analysis is a technique that allows quantitative
analyses of networks comprising direct trial evidence. It provides
estimates of comparative effectiveness taking account of the rela-
tive weight of the available direct and indirect evidence for any
given comparison. It also provides an opportunity to observe
incoherence between the various trials included in the network,
and to take account of this in decision-making. It allows analysts,
where possible, to adjust for heterogeneity between trials that
may underlie incoherence. This may provide predictions for
patients with particular characteristics.
Turning to the more speciﬁc issues raised by Edwards and
Borrill [1], our original analysis [2] could more accurately have
been referred to as an analysis of patients who had received prior
chemotherapy rather than second-line treatment. This would
have reﬂected the inclusion criteria for the majority of the trials
and the lack of evidence regarding an effect of the number of lines
of prior treatment on the relative effectiveness of treatment: the
univariate subgroup analysis published for the BR21 trial did not
indicate any difference in relative treatment effect between
patients who had previously received one or two or more lines of
treatment, and the subgroup analysis conducted for Iressa Sur-
vival Evaluation in Lung Cancer (ISEL) trial did not ﬁnd a
statistically signiﬁcant difference between patients with one or
two previous chemotherapy regimens.
It is difﬁcult to evaluate the supposition that the lack of
effectiveness observed within the ISEL trial was due to the pro-
portion of patients refractory to prior chemotherapy. It was not
possible to determine whether this characteristic modiﬁed rela-
tive treatment effectiveness within the ISEL trial, and the propor-
tion of refractory patients was not reported for the other trials.
This situation does illustrate the paradox that tightly deﬁned
inclusion criteria may enhance the internal validity of a trial at
the expense of generalizability.
It would be helpful to be able to account for the effect of
treatment history on the relative response to treatment; this
would both improve the accuracy of comparisons between treat-
ments and also allow predictions to be made for patients with
speciﬁc characteristics. Analyses of sets of trial evidence may
further encourage trialists to provide data or report results that
facilitate adjustment for heterogeneity between trials.
Finally, rerunning our original analysis with the data supplied
in Edwards and Borrill’s Table 1 [2] still results in incoherence
between the direct estimate of the hazard ratio of docetaxel
compared with placebo (mean 0.50, 95% conﬁdence interval
0.29–0.79), provided by the small TAX317 trial, and the com-
bined estimate (0.77, 0.62–0.93), including data from the ISEL,
SIGN, and INTEREST trials. This may be due to chance, lack of
transitivity on the hazard ratio scale, or heterogeneity between
trials. Regardless of its source, this incoherence should be taken
into account by decision-makers selecting the most appropriate
treatment for patients based on the body of available trial
evidence.—Neil Hawkins, PhD, MSc, David A. Scott, MA, Beth
Woods, MSc, Oxford Outcomes, Botley, Oxford, UK; and
Nicholas Thatcher, PhD, MD, Department of Medical Oncology,
Christie Hospital NHS Foundation Trust, Manchester, UK.
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